LABORATORY RESEARCH Distinct EMT Programs Control Normal Mammary Stem Cells and Tumor-Initiating Cells Using genetically engineered knock-in reporter mouse lines, investigators showed that normal gland-reconstituting mammary stem cells residing in the basal layer of the mammary epithelium and breast tumor-initiating cells originating in the luminal layer exploit the paralogous epithelial-to-mesenchymal transition (EMT)-inducing transcription factor Slug and Snail, respectively, which induce distinct EMT programs. [Nature] Abstract | Press Release Adaptive Immune Regulation of Mammary Postnatal Organogenesis Investigators showed that adaptive immune responses participate in the normal postnatal development of a non-lymphoid epithelial tissue. They found that antigen-mediated interactions between mammary antigen-presenting cells and interferon-γ-producing CD4+ T helper 1 cells participate in mammary gland postnatal organogenesis as negative regulators, locally orchestrating epithelial rearrangement. [Dev Cell] Abstract | Graphical Abstract | Press Release Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization The authors report the remarkable inter-individual differences in differentiation capabilities as documented by phenotypic heterogeneity in stem-progenitor-mature cell hierarchy of the normal breast. [Sci Rep] Full Article Physicochemical and Biological Characterization of Chitosan-MicroRNA Nanocomplexes for Gene Delivery to MCF-7 Breast Cancer Cells Researchers investigated the physicochemical/biophysical properties of chitosan–hsa-microRNA-145 nanocomplexes and the biological responses of MCF-7 breast cancer cells cultured in vitro. [Sci Rep] Full Article Activation of RARα Induces Autophagy in SKBR3 Breast Cancer Cells and Depletion of Key Autophagy Genes Enhances ATRA Toxicity The authors tested if autophagy is activated by all-trans retinoic acid (ATRA) in mammary tumor cells and if modulation of autophagy might be a potential novel treatment strategy. ATRA induced autophagic flux in ATRA-sensitive but not in ATRA-resistant human breast cancer cells. [Cell Death Dis] Full Article Apoptosis Induction in Human Breast Cancer (MCF-7) Cells by a Novel Venom L-Amino Acid Oxidase (Rusvinoxidase) Is Independent of Its Enzymatic Activity and Is Accompanied by Caspase-7 Activation and Reactive Oxygen Species Production Researchers report the elucidation of a mechanism of apoptosis induction in breast cancer cells by an L-amino acid oxidase, rusvinoxidase, purified from the venom of Daboia russelii russelii. [Apoptosis] Abstract Reversal of Efflux of an Anticancer Drug in Human Drug-Resistant Breast Cancer Cells by Inhibition of Protein Kinase Cα (PKCα) Activity PKCα activity was confirmed by measurement of phosphorylation levels of a PKCα-specific peptide substrate, showing relatively higher basal activity in drug-resistant MCF-7/ADR cells than that in drug-sensitive MCF-7 cells. [Tumor Biol] Abstract Gene Expression Signatures of Breast Cancer Stem and Progenitor Cells Do Not Exhibit Features of Warburg Metabolism While benign stem/progenitor cells exhibited few significant inter-group differences in expression of genes involved in hypoxia regulation or glucose metabolism, breast cancer stem/progenitor cells demonstrated significant inter-group variability. [Stem Cell Res Ther] Full Article Differential Ratios of Omega Fatty Acids (AA/EPA+DHA) Modulate Growth, Lipid Peroxidation and Expression of Tumor Regulatory MARBPs in Breast Cancer Cell Lines MCF7 and MDA-MB-231 Investigators determined whether different ratios of n6/n3 (AA/EPA+DHA) fatty acids could modulate the cell viability, lipid peroxidation, total cellular fatty acid composition and expression of tumor regulatory matrix attachment region binding proteins (MARBPs) in breast cancer cell lines and in non-cancerous, MCF10A cells. [PLoS One] Full Article CLINICAL RESEARCH Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer that Progressed on Endocrine Therapy This Phase II trial evaluated the efficacy and safety of cixutumumab, a human anti-insulin-like growth factor-receptor 1 (IGF-1R) monoclonal IgG1 antibody, and explored potential biomarkers in postmenopausal women with hormone receptor-positive breast cancer. [Clin Cancer Res] Abstract Metformin Intervention in Obese Non-Diabetic Patients with Breast Cancer: Phase II Randomized, Double-Blind, Placebo-Controlled Trial This randomized, double-blind, placebo-controlled trial was performed to evaluate the efficacy of metformin for controlling physical and metabolic profiles related to prognosis and adverse events in non-diabetic breast cancer patients. [Breast Cancer Res Treat] Abstract |